AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+15%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$4.57B
AUM Growth
+$4.57B
(+10%)
Cap. Flow
+$57.2M
Cap. Flow
% of AUM
1.25%
Top 10 Holdings %
Top 10 Hldgs %
94.28%
Holding
71
New
8
Increased
20
Reduced
1
Closed
8
Top Buys
| 1 |
Goldman Sachs
GS
|
$31.4M |
| 2 |
CELG
Celgene Corp
CELG
|
$26M |
| 3 |
Bank of America
BAC
|
$13.5M |
| 4 |
Aptiv
APTV
|
$13.1M |
| 5 |
Citigroup
C
|
$10.4M |
Top Sells
| 1 |
LNKD
LinkedIn Corporation
LNKD
|
$22.5M |
| 2 |
Yum! Brands
YUM
|
$21.9M |
| 3 |
MBLY
Mobileye N.V.
MBLY
|
$14.8M |
| 4 |
General Motors
GM
|
$13.6M |
| 5 |
Visa
V
|
$13.6M |
Sector Composition
| 1 | Consumer Staples | 64.63% |
| 2 | Healthcare | 21.22% |
| 3 | Consumer Discretionary | 10.47% |
| 4 | Financials | 2.59% |
| 5 | Industrials | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
| $2.95B | 57.56% | 114,987,547 | – | – |
|
2
Lexicon Pharmaceuticals
LXRX
$400M
| $687M | 13.41% | 57,517,977 | – | – |
|
|
WW
3
DELISTED
WW International
WW
| $428M | 8.35% | 29,443,300 | – | – |
|
4
Incyte
INCY
$16.5B
| $43.5M | 0.85% | 600,000 +30,000 | +5% | +$2.17M |
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $37.7M | 0.73% | 600,000 +125,000 | +26% | +$7.85M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $36M | 0.7% | 360,000 +260,000 | +260% | +$26M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $33M | 0.64% | 400,000 +125,000 | +45% | +$10.3M |
|
|
8
Goldman Sachs
GS
$226B
| $31.4M | 0.61% | +200,000 | New | +$31.4M |
|
9
Alibaba
BABA
$322B
| $29.6M | 0.58% | 375,000 +75,000 | +25% | +$5.93M |
|
10
Nektar Therapeutics
NKTR
$568M
| $27.5M | 0.54% | 2,000,000 +400,000 | +25% | +$5.5M |
|
|
KITE
11
DELISTED
Kite Pharma, Inc.
KITE
| $22.3M | 0.43% | 485,000 +135,000 | +39% | +$6.2M |
|
|
BLUE
12
DELISTED
bluebird bio
BLUE
| $21.3M | 0.41% | 500,000 +140,000 | +39% | +$5.95M |
|
|
13
Aptiv
APTV
$17.3B
| $20.6M | 0.4% | 275,000 +175,000 | +175% | +$13.1M |
|
14
Mastercard
MA
$538B
| $18.9M | 0.37% | 200,000 -100,000 | -33% | -$9.45M |
|
15
Ionis Pharmaceuticals
IONS
$6.79B
| $14.2M | 0.28% | 350,000 | – | – |
|
16
Agios Pharmaceuticals
AGIO
$2.19B
| $13.6M | 0.27% | 335,000 +60,000 | +22% | +$2.44M |
|
|
17
Bank of America
BAC
$376B
| $13.5M | 0.26% | +1,000,000 | New | +$13.5M |
|
18
Morgan Stanley
MS
$240B
| $12.5M | 0.24% | 500,000 +200,000 | +67% | +$5M |
|
19
JPMorgan Chase
JPM
$829B
| $11.8M | 0.23% | 200,000 | – | – |
|
|
ARRY
20
DELISTED
Array Biopharma Inc
ARRY
| $10.9M | 0.21% | 3,710,000 | – | – |
|
|
21
Citigroup
C
$178B
| $10.4M | 0.2% | +250,000 | New | +$10.4M |
|
22
MetLife
MET
$54.1B
| $10.3M | 0.2% | +235,000 | New | +$10.3M |
|
|
JUNO
23
DELISTED
Juno Therapeutics, Inc.
JUNO
| $10.1M | 0.2% | 265,000 +75,000 | +39% | +$2.86M |
|
24
Delta Air Lines
DAL
$40.3B
| $9.74M | 0.19% | 200,000 +100,000 | +100% | +$4.87M |
|
25
LendingClub
LC
$1.97B
| $9.34M | 0.18% | 1,125,000 +50,000 | +5% | +$415K |
|